Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist.

[1] It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials.

However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.

[2] This article about an anxiolytic is a stub.

You can help Wikipedia by expanding it.